Press release
New technology to “unlock” NHS records to revolutionise how we take medicine
January 11, 2023Business Services
London, UK – New technology which can “unlock” medication records has been awarded £1m in fresh funding by Innovate UK.
STORM Therapeutics Expands R&D Leadership Team
January 10, 2023Business Services
10 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule …
Positive Initial Data Analysis in POLB 001 LPS Challenge Trial
January 9, 2023Business Services
9 January 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical …
Novo Holdings invests in proteomics technology company, Evosep
January 9, 2023Business Services
The proceeds from the investment by Novo Holdings will be used to advance clinical applications of proteomics enabled by Evosep’s …
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
January 6, 2023Business Services
Strasbourg, France, January 6, 2023, 7:30 a.m.
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
January 5, 2023Medical Communications
AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for …
Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer
January 5, 2023Business Services
BASEL, Switzerland – 5th January 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced …
iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program
January 5, 2023Business Services
Geneva, Switzerland and Amsterdam, The Netherlands, 5 January – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that …
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
January 5, 2023Business Services
Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …
Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders
January 5, 2023Business Services
Tokyo, Japan and Cambridge, UK, 5 January 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
January 4, 2023Business Services
Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V.
ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
January 4, 2023Business Services
Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to …
Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders
January 4, 2023Business Services
London, UK – 4 January 2023. Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing …
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
January 3, 2023Business Services
Milan, Italy, Jan. 3, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
January 3, 2023Business Services
BEERSE, BELGIUM, 3 January 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a …
Latest content
Acumentis CEO Herspiegel steps down as Burden assumes role
